keyword
MENU ▼
Read by QxMD icon Read
search

psoriasis cardiovascular event

keyword
https://www.readbyqxmd.com/read/28735613/does-treatment-of-psoriasis-reduce-cardiovascular-comorbidities
#1
Mark Lebwohl
Psoriasis has been associated with an increase in myocardial infarctions. Several registries have shown reductions in major adverse cardiovascular events in psoriasis patients and rheumatoid arthritis patients treated with tumor necrosis factor-α antagonists. Many assume that the reduction in cardiovascular events can be attributed to the anti-inflammatory effect of tumor necrosis factor blockers, but a 52-week study conducted by Bissonnette and coworkers failed to show a reduction in cardiovascular inflammation in psoriasis patients treated with adalimumab...
August 2017: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/28670544/randomized-placebo-control-study-of-metformin-in-psoriasis-patients-with-metabolic-syndrome-systemic-treatment-cohort
#2
Surjit Singh, Anil Bhansali
BACKGROUND: Psoriasis has been found to be associated with obesity, metabolic syndrome (MS), diabetes, and cardiovascular risk factors. Metformin treatment showed improvement in cardiovascular risk factors and hyperinsulinemia. OBJECTIVE: To evaluate the efficacy and safety of metformin in psoriasis patients with MS. MATERIALS AND METHODS: This was a single-center, parallel-group, randomized, open-label study with blinded end point assessment of metformin (1000 mg once daily for 12 weeks; n = 20) and placebo (n = 18) in psoriasis patients with MS...
July 2017: Indian Journal of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28610662/clinical-diagnostic-and-therapeutic-implications-in-psoriasis-associated-with-cardiovascular-disease
#3
C Bonanad, E González-Parra, R Rivera, J M Carrascosa, E Daudén, A Olveira, R Botella-Estrada
In recent years the concept of psoriasis as a systemic disease has gained acceptance due to its association with numerous comorbid conditions, particularly atherosclerosis and cardiovascular disease. Several studies have shown that patients with psoriasis, especially younger patients and those with more severe forms of psoriasis or with psoriatic arthritis, have a higher prevalence of risk factors and metabolic syndrome, as well as an increased risk of major cardiovascular events such as myocardial infarction, cerebrovascular disease, and peripheral arterial disease...
June 10, 2017: Actas Dermo-sifiliográficas
https://www.readbyqxmd.com/read/28601812/cardiovascular-and-type-2-diabetes-morbidity-and-all-cause-mortality-among-diverse-chronic-inflammatory-disorders
#4
Alex Dregan, Phil Chowienczyk, Mariam Molokhia
OBJECTIVES: The present study aimed to assess the relationship between inflammatory disorders with cardiometabolic diseases and mortality within a community-based population. METHODS: The UK Biobank data were used to conduct two investigations: a cross-sectional study to estimate cardiometabolic risk and a prospective cohort study to estimate mortality risk. Binary regression analyses were used to model the association between coronary heart disease, stroke, type 2 diabetes, venous thromboembolism and peripheral artery disease diagnoses with seven inflammatory disorders (eg, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), psoriasis, ankylosing spondylitis (AS), systemic vasculitis, Crohn's disease and ulcerative colitis (UC))...
June 10, 2017: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/28573499/effectiveness-of-lipid-lowering-statin-therapy-in-patients-with-and-without-psoriasis
#5
William C Ports, Rana Fayyad, David A DeMicco, Rachel Laskey, Robert Wolk
BACKGROUND: Psoriasis is associated with dyslipidemia and metabolic syndrome, and has been linked to an increased cardiovascular risk. The aim of this study was to compare baseline characteristics and effects of statin therapy on lipid levels and cardiovascular outcomes in patients with and without psoriasis. METHODS: This post-hoc analysis assessed patients from one primary cardiovascular prevention statin trial (Collaborative AtoRvastatin Diabetes Study [CARDS]) and two secondary cardiovascular prevention statin trials (Treating to New Targets [TNT] and Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL])...
August 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/28564678/association-between-skin-and-aortic-vascular-inflammation-in-patients-with-psoriasis-a-case-cohort-study-using-positron-emission-tomography-computed-tomography
#6
Amit K Dey, Aditya A Joshi, Abhishek Chaturvedi, Joseph B Lerman, Tsion M Aberra, Justin A Rodante, Heather L Teague, Charlotte L Harrington, Joshua P Rivers, Jonathan H Chung, Mohammad Tarek Kabbany, Balaji Natarajan, Joanna I Silverman, Qimin Ng, Gregory E Sanda, Alexander V Sorokin, Yvonne Baumer, Emily Gerson, Ronald B Prussick, Alison Ehrlich, Lawrence J Green, Benjamin N Lockshin, Mark A Ahlman, Martin P Playford, Joel M Gelfand, Nehal N Mehta
Importance: Inflammation is critical in the development of atherosclerosis. Psoriasis is a chronic inflammatory skin disease that is associated with increased vascular inflammation by 18fluorodeoxyglucose positron emission tomography/computed tomography in vivo and future cardiovascular events. It provides a human model to understand the effect of treating inflammation in a target organ (eg, the skin) on vascular diseases. Objective: To investigate the association between change in skin disease severity and change in vascular inflammation at 1 year and to characterize the impact of 1 year of anti-tumor necrosis factor therapy on vascular inflammation...
May 31, 2017: JAMA Cardiology
https://www.readbyqxmd.com/read/28441904/the-safety-of-ustekinumab-for-the-treatment-of-psoriatic-arthritis
#7
REVIEW
A López-Ferrer, A Laiz, L Puig
The cytokines interleukin (IL)-12 and IL-23 have been involved in the pathogenesis of psoriasis and psoriatic arthritis. Ustekinumab is a fully human monoclonal antibody targeting the p40 subunit shared by IL-12 and IL-23. Ustekinumab prevents the interaction of IL-12 and IL-23 binding to their receptors, blocking the T1 and T17 inflammatory pathways. Ustekinumab has been evaluated for the treatment of various chronic immune mediated diseases including psoriasis and psoriatic arthritis (PsA). Most of the data regarding the safety of ustekinumab come from the experience treating patients with psoriasis, but clinical trials have demonstrated its efficacy and safety in the treatment of both diseases...
June 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28423301/risankizumab-versus-ustekinumab-for-moderate-to-severe-plaque-psoriasis
#8
RANDOMIZED CONTROLLED TRIAL
Kim A Papp, Andrew Blauvelt, Michael Bukhalo, Melinda Gooderham, James G Krueger, Jean-Philippe Lacour, Alan Menter, Sandra Philipp, Howard Sofen, Stephen Tyring, Beate R Berner, Sudha Visvanathan, Chandrasena Pamulapati, Nathan Bennett, Mary Flack, Paul Scholl, Steven J Padula
BACKGROUND: Interleukin-23 is thought to be critical to the pathogenesis of psoriasis. We compared risankizumab (BI 655066), a humanized IgG1 monoclonal antibody that inhibits interleukin-23 by specifically targeting the p19 subunit and thus prevents interleukin-23 signaling, and ustekinumab, an interleukin-12 and interleukin-23 inhibitor, in patients with moderate-to-severe plaque psoriasis. METHODS: We randomly assigned a total of 166 patients to receive subcutaneous injections of risankizumab (a single 18-mg dose at week 0 or 90-mg or 180-mg doses at weeks 0, 4, and 16) or ustekinumab (45 or 90 mg, according to body weight, at weeks 0, 4, and 16)...
April 20, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28384966/metabolic-syndrome-in-psoriasis-among-urban-south-indians-a-case-control-study-using-sam-ncep-criteria
#9
Banavasi S Girisha, Neetha Thomas
INTRODUCTION: Psoriasis is a chronic inflammatory disease of the skin associated with increased cardiovascular morbidity. Metabolic syndrome is a significant forecaster of cardiovascular events. AIM: To assess the association of metabolic syndrome and its components in patients with psoriasis and to compare it with the age and sex matched control group. MATERIALS AND METHODS: We conducted a hospital based case-control study on 156 adult patients with chronic plaque psoriasis and 156 patients with skin diseases other than psoriasis...
February 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28371532/prevalence-of-metabolic-syndrome-in-chinese-psoriasis-patients-a-hospital-based-cross-sectional-study
#10
Xin-Yu Gui, Xiao-Ling Yu, Hong-Zhong Jin, Ya-Gang Zuo, Chao Wu
AIMS/INTRODUCTION: Psoriasis, a chronic autoimmune skin disorder, is believed to contribute to cardiovascular diseases and metabolic syndrome. Psoriasis's association with the components of metabolic syndrome has been reported previously. However, large-scale cross-sectional studies about psoriasis and metabolic syndrome are rare in China. MATERIALS AND METHODS: We assessed the prevalence of metabolic syndrome in Chinese psoriasis patients and controls. RESULTS: A total of 859 psoriasis patients and 1,718 controls were recruited in an age- and sex-matched cross-sectional study...
March 30, 2017: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/28258057/psoriasis-as-a-human-model-of-disease-to-study-inflammatory-atherogenesis
#11
REVIEW
Charlotte L Harrington, Amit K Dey, Raza Yunus, Aditya A Joshi, Nehal N Mehta
Inflammation is known to play a significant role in the process of atherogenesis and cardiovascular disease (CVD). Indeed, patients with chronic inflammatory diseases are at increased risk for cardiovascular events. However, the mechanisms linking chronic inflammation and CVD remain poorly understood. Psoriasis, a chronic inflammatory skin disease associated with a greater risk of early cardiovascular events, provides a suitable human model to study the pathophysiology of inflammatory atherogenesis in humans...
May 1, 2017: American Journal of Physiology. Heart and Circulatory Physiology
https://www.readbyqxmd.com/read/28213804/psoriasis-and-cardiovascular-events-updating-the-evidence
#12
Line Raaby, Ole Ahlehoff, Annette de Thurah
So far, systematic reviews have suggested an increased risk of cardiovascular diseases (CVD) in psoriatic patients, though some results have been conflicting. The aim of this study was to update the current level of evidence through a systematic search in MEDLINE, EMBASE and Cochrane Central Register databases. In total, 13 high-quality observational studies estimating the incidence of CVD were included. Patients with mild psoriasis had an increased risk of stroke [Hazard ratio (HR) = 1.10, 95% CI: 1.0-1...
April 2017: Archives of Dermatological Research
https://www.readbyqxmd.com/read/28168661/psoriasis-in-systemic-lupus-erythematosus-a-single-center-experience
#13
Konstantinos Tselios, Kristy Su-Ying Yap, Rattapol Pakchotanon, Ari Polachek, Jiandong Su, Murray B Urowitz, Dafna D Gladman
The coexistence of psoriasis with systemic lupus erythematosus (SLE) has been reported in limited case series, raising hypotheses about shared pathogenetic mechanisms. Nevertheless, important differences regarding treatment do exist. The aim of the present study was to determine the prevalence and characteristics of psoriasis in a defined cohort of lupus patients. Patients with psoriasis were retrieved from the University of Toronto Lupus Clinic from its inception in 1970 up to 2015. Charts were hand-searched to collect information concerning demographic, clinical, and therapeutic variables...
February 6, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28156019/excessive-angiogenesis-associated-with-psoriasis-as-a-cause-for-cardiovascular-ischaemia
#14
Nina Malecic, Helen S Young
Psoriasis, a common disease affecting 2-3% of the UK population, produces significant impairment of quality of life and is an immense burden on sufferers and their families. Psoriasis is associated with significant cardiovascular co-morbidity and the metabolic syndrome. Angiogenesis, a relatively under-researched component of psoriasis, is a key factor in pathogenesis of psoriasis and also contributes to the development of atherosclerosis. Vascular endothelial growth factor (VEGF) is a well established mediator of pathological angiogenesis which is upregulated in psoriasis...
February 3, 2017: Experimental Dermatology
https://www.readbyqxmd.com/read/28118966/mortality-in-patients-with-psoriasis-a-retrospective-cohort-study
#15
Walter Masson, Emiliano Rossi, María Laura Galimberti, Juan Krauss, José Navarro Estrada, Ricardo Galimberti, Arturo Cagide
BACKGROUND AND OBJECTIVES: The immune and inflammatory pathways involved in psoriasis could favor the development of atherosclerosis, consequently increasing mortality. The objectives of this study were: 1) to assess the mortality of a population with psoriasis compared to a control group, and 2) to assess the prevalence of cardiovascular risk factors. PATIENTS AND METHOD: A retrospective cohort was analyzed from a secondary database (electronic medical record)...
January 21, 2017: Medicina Clínica
https://www.readbyqxmd.com/read/28107570/efficacy-and-safety-of-interleukin-17-antagonists-in-patients-with-plaque-psoriasis-a-meta-analysis-from-phase-3-randomized-controlled-trials
#16
D Wu, S-Y Hou, S Zhao, L-X Hou, T Jiao, N-N Xu, N Zhang
BACKGROUND: The interleukin-17 (IL-17) cytokine pathway plays a key role in the development of psoriasis. Antibodies targeting IL-17 or blocking its receptor may be a new therapeutic approach for psoriasis. To assist treatment selection in daily practice, it is essential to understand the benefit and risk profile of IL-17 antagonists. OBJECTIVE: We performed a meta-analysis to evaluate the efficacy and safety of IL-17 antagonists in patients with psoriasis. METHODS: We searched a number of databases for relevant randomized controlled trials (RCTs) published before May 2016...
January 20, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28099594/diagnosis-and-underdiagnosis-of-comorbidities-in-psoriasis-patients-need-for-a-multidisciplinary-approach
#17
Gleison Vieira Duarte, Maria de Fátima S P de Oliveira, Ivonise Follador, Thadeu Santo Silva, Edgar Marcelino de Carvalho
BACKGROUND: Psoriasis is an immune-mediated disease that manifests predominantly in the skin, although systemic involvement may also occur. Although associated comorbidities have long been recognized and despite several studies indicating psoriasis as an independent risk factor for cardiovascular events, little has been done in general medical practice regardind screening. In the United States, less than 50% of clinicians are aware of these recommendations. OBJECTIVE: To identify the prevalence of these comorbidities in 296 patients followed up at a university dermatology clinic...
November 2016: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/28012564/an-intensified-dosing-schedule-of-subcutaneous-methotrexate-in-patients-with-moderate-to-severe-plaque-type-psoriasis-metop-a-52-week-multicentre-randomised-double-blind-placebo-controlled-phase-3-trial
#18
Richard B Warren, Ulrich Mrowietz, Ralph von Kiedrowski, Johannes Niesmann, Dagmar Wilsmann-Theis, Kamran Ghoreschi, Ina Zschocke, Thomas M Falk, Norbert Blödorn-Schlicht, Kristian Reich
BACKGROUND: Methotrexate is one of the most commonly used systemic drugs for the treatment of moderate to severe psoriasis; however, high-quality evidence for its use is sparse and limited to use of oral dosing. We aimed to assess the effect of an intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis. METHODS: We did this prospective, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (METOP) at 16 sites in Germany, France, the Netherlands, and the UK...
February 4, 2017: Lancet
https://www.readbyqxmd.com/read/27957253/increased-levels-of-circulating-platelet-derived-microparticles-in-psoriasis-possible-implications-for-the-associated-cardiovascular-risk
#19
Evangelia Papadavid, Konstantina Diamanti, Aris Spathis, Maria Varoudi, Ioanna Andreadou, Kostas Gravanis, Kostas Theodoropoulos, Petros Karakitsos, John Lekakis, Dimitrios Rigopoulos, Ignatios Ikonomidis
AIM: To evaluate platelet activation markers in psoriasis patients, compared to controls, and investigate their association with the inflammatory burden of psoriasis. METHODS: Forty psoriatic patients without cardiovascular disease, and 12 healthy controls were subjected to measurement of baseline platelet CD62P, CD63 and CD42b expression, platelet-leukocyte complexes, i.e., platelet-monocyte complexes (PMC), platelet-neutrophil complexes (PNC) and platelet-lymphocyte complexes, and concentrations of platelet-derived microparticles (PMPs) using flow cytometry...
November 26, 2016: World Journal of Cardiology
https://www.readbyqxmd.com/read/27894789/cardiovascular-event-risk-assessment-in-psoriasis-patients-treated-with-tumor-necrosis-factor-%C3%AE-inhibitors-versus-methotrexate
#20
COMPARATIVE STUDY
Jashin J Wu, Annie Guérin, Murali Sundaram, Katherine Dea, Martin Cloutier, Parvez Mulani
BACKGROUND: Psoriasis is associated with increased risk for cardiovascular disease. OBJECTIVE: To compare major cardiovascular event risk in psoriasis patients receiving methotrexate or tumor necrosis factor-α inhibitor (TNFi) and to assess TNFi treatment duration impact on major cardiovascular event risk. METHODS: Adult psoriasis patients with ≥2 TNFi or methotrexate prescriptions in the Truven MarketScan Databases (Q1 2000-Q3 2011) were classified as TNFi or methotrexate users...
January 2017: Journal of the American Academy of Dermatology
keyword
keyword
114302
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"